Martin S Blumenreich, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 560 S Maple St, Suite 100, Waconia, MN 55387 Phone: 952-442-6606 Fax: 952-442-6604 |
News Archive
Carefx Corporation, a leading provider of interoperable workflow solutions, and Imprivata®, Inc., the employee access management company, today announced that Johns Hopkins Health System, an internationally recognized group of healthcare institutions, has selected Carefx Fusionfx and Imprivata OneSign to deliver an integrated clinical access solution that streamlines access to workstations, applications and patient data. The complete, integrated system will launch in early 2010.
National Health Investors, Inc. announced today it has closed a $11.5 million purchase/leaseback transaction with Bickford Senior Living and its affiliates involving two assisted living facilities in Iowa and one in Indiana. The assisted living communities, two of which were built in 1998 and one in 2005, total 102 units and attract 100% private payment for services. The purchase price was funded from NHI's revolving credit facility.
Forest Laboratories, and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of major depressive disorder.
Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine.
Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety
› Verified 9 days ago